Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
1. ABT expected to report Q2 earnings of $1.25 per share. 2. Projected revenue for Q2 is $11.02 billion, up from $10.38 billion. 3. The FDA approved ABT's Tendyne™ mitral valve replacement system. 4. Analysts have mostly positive ratings with increased price targets. 5. Shares of ABT rose 0.1% to close at $131.49.